163 related articles for article (PubMed ID: 33894496)
1. Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
Bogart JA; Wang X; Masters GA; Gao J; Komaki R; Gaspar LE; Heymach JV; Dobelbower MC; Kuzma C; Stinchcombe TE; Vokes EE
Lung Cancer; 2021 Jun; 156():68-71. PubMed ID: 33894496
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Grønberg BH; Halvorsen TO; Fløtten Ø; Brustugun OT; Brunsvig PF; Aasebø U; Bremnes RM; Tollåli T; Hornslien K; Aksnessæther BY; Liaaen ED; Sundstrøm S;
Acta Oncol; 2016 May; 55(5):591-7. PubMed ID: 26494411
[TBL] [Abstract][Full Text] [Related]
3. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Bogart J; Wang X; Masters G; Gao J; Komaki R; Gaspar LE; Heymach J; Bonner J; Kuzma C; Waqar S; Petty W; Stinchcombe TE; Bradley JD; Vokes E
J Clin Oncol; 2023 May; 41(13):2394-2402. PubMed ID: 36623230
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT; Halvorsen TO; Fløtten Ø; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Grønberg BH
Lung Cancer; 2022 Apr; 166():49-57. PubMed ID: 35183991
[TBL] [Abstract][Full Text] [Related]
5. [A prospective randomized study of the radiotherapy volume for limited-stage small cell lung cancer: a preliminary report].
Hu X; Bao Y; Zhang L; Cheng Y; Li K; Wang W; Liu Y; He H; Sun Z; Zhuang T; Wang Y; Chen J; Liang Y; Zhang Y; Zhao H; Wang F; Chen M
Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):691-9. PubMed ID: 20673485
[TBL] [Abstract][Full Text] [Related]
6. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
[TBL] [Abstract][Full Text] [Related]
7. Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.
Bogart JA; Watson D; McClay EF; Evans L; Herndon JE; Laurie F; Seagren SL; Fitzgerald TJ; Vokes E; Green MR
Lung Cancer; 2008 Oct; 62(1):92-8. PubMed ID: 18367288
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
9. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.
Takada M; Fukuoka M; Kawahara M; Sugiura T; Yokoyama A; Yokota S; Nishiwaki Y; Watanabe K; Noda K; Tamura T; Fukuda H; Saijo N
J Clin Oncol; 2002 Jul; 20(14):3054-60. PubMed ID: 12118018
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.
Sun JM; Ahn YC; Choi EK; Ahn MJ; Ahn JS; Lee SH; Lee DH; Pyo H; Song SY; Jung SH; Jo JS; Jo J; Sohn HJ; Suh C; Lee JS; Kim SW; Park K
Ann Oncol; 2013 Aug; 24(8):2088-92. PubMed ID: 23592701
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
12. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
13. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.
Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J
Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846
[TBL] [Abstract][Full Text] [Related]
14. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
16. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
Hu X; Bao Y; Xu YJ; Zhu HN; Liu JS; Zhang L; Guo Y; Jin Y; Wang J; Ma HL; Xu XL; Song ZB; Tang HR; Peng F; Fang M; Kong Y; Chen MY; Dong BQ; Zhu L; Yu C; Yu XM; Hong W; Fan Y; Zhang YP; Chen PC; Zhao Q; Jiang YH; Zhou XM; Chen QX; Sun WY; Mao WM; Chen M
Cancer; 2020 Feb; 126(4):840-849. PubMed ID: 31714592
[TBL] [Abstract][Full Text] [Related]
17. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.
Komaki R; Scott C; Ettinger D; Lee JS; Fossella FV; Curran W; Evans RF; Rubin P; Byhardt RW
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):149-55. PubMed ID: 9212017
[TBL] [Abstract][Full Text] [Related]
19. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
Bogart JA; Herndon JE; Lyss AP; Watson D; Miller AA; Lee ME; Turrisi AT; Green MR;
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):460-8. PubMed ID: 15145163
[TBL] [Abstract][Full Text] [Related]
20. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Garces YI; Okuno SH; Schild SE; Mandrekar SJ; Bot BM; Martens JM; Wender DB; Soori GS; Moore DF; Kozelsky TF; Jett JR
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):995-1001. PubMed ID: 17336213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
